Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study - Concepedia

Concepedia

Publication | Open Access

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

DOI Full Paper Access

132

Citations

26

References

2015

Year

Miguel Martín, Sibylle Loibl, Gϋnter von Minckwitz, Serafín Morales, Noelia Martínez-Jáñez, Ángel Guerrero, Antonio Antón, Bahriye Aktas, Winfried Schoenegg, Montserrat Muñoz-Mateu,

Journal of Clinical Oncology

Abstract

The addition of bevacizumab to ET in first-line treatment failed to produce a statistically significant increase in PFS or OS in women with HER2-negative/hormone receptor-positive advanced breast cancer.

References

	Year	Citations

Page 1